Interstitial Lung Disease Pipeline Grows as 120+ Pharma Companies Advance Novel Lung Disease Therapies, Finds DelveInsight | Roche, aTyr Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, PureTech Health

DelveInsight's "Interstitial Lung Disease (ILD) - Pipeline Insight, 2026" report provides comprehensive insights about 120+ companies developing over 120 pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the ILD pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Interstitial Lung Disease treatment landscape. Learn more about the evolving ILD pipeline today @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Interstitial Lung Disease Pipeline Report

• In September 10, 2025, U.S. FDA approved Boehringer Ingelheim's JASCAYD (nerandomilast tablets) as the first new treatment option for adults with Idiopathic Pulmonary Fibrosis in over a decade.
• In August 2025, the FDA granted Endeavor BioMedicines' investigational therapy, taladegib, orphan drug designation for the treatment of rare conditions such as IPF.
• In June 2025, Insilico Medicine announced positive results from its phase 2a study of rentosertib, an AI-designed drug showing improved lung function in IPF patients.
• In March 2024, Pliant announced an accelerated development plan for bexotegrast (BEACON-IPF) as a Phase 2b/3 adaptive design to shorten the timeline to Phase 3 data.
• In February 2024, Syndax reported that enrollment was ongoing in the Phase 2 trial for axatilimab in IPF, following the grant of Orphan Drug Status by the FDA.
• In September 2023, Bristol Myers Squibb presented positive Phase 2 data for BMS-986278, showing a 69% relative reduction in the rate of decline in percent-predicted forced vital capacity.
• Interstitial lung disease (ILD) describes a heterogeneous group of disorders characterized by inflammation and fibrosis, or scarring, of the lung parenchyma.
• DelveInsight's Interstitial Lung Disease Pipeline Insight report depicts a robust clinical development space with 120+ active players advancing over 120 pipeline therapies globally.
• The leading Interstitial Lung Disease companies include Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, Bristol-Myers Squibb, PureTech Health, Novartis, and others.

Download for updates and the latest revolution in ILD care @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Interstitial Lung Disease Emerging Drugs Profile

• BMS-986278: Bristol-Myers Squibb
BMS-986278 is a potential first-in-class, oral lysophosphatidic acid receptor 1 (LPA1) antagonist being developed by Bristol-Myers Squibb. LPA1 signaling is known to be involved in the development of pulmonary fibrosis, and by antagonizing this receptor, BMS-986278 aims to reduce the fibrotic process in the lungs. Currently, this candidate is in Phase III clinical development (ALOFT trial) for treatment of patients with IPF and progressive pulmonary fibrosis.

• Efzofitimod: aTyr Pharma
Efzofitimod is being investigated in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is currently in a 2-Part study, with Part A being a double-blind, randomized, placebo-controlled, proof-of-concept study to evaluate efficacy, safety, and tolerability. The primary objective is to evaluate the therapeutic potential of efzofitimod in reducing lung inflammation and fibrosis associated with connective tissue diseases.

• LYT-100: PureTech Health
LYT-100 (de-deuterated pirfenidone) is an analogue of the approved antifibrotic agent pirfenidone, designed to maintain therapeutic efficacy while potentially improving the safety and tolerability profile. It is currently in clinical trials for conditions like idiopathic pulmonary fibrosis, aiming to address the high rate of discontinuations often seen with standard antifibrotic therapies due to side effects.

For more information on the Interstitial Lung Disease Emerging Drugs Profile, download DelveInsight's comprehensive Interstitial Lung Disease Pipeline Insight report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Interstitial Lung Disease Pipeline Report Provides

• Detailed insights about companies developing therapies for Interstitial Lung Disease, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for ILD treatment.
• ILD companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ILD drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Interstitial Lung Disease market.

Learn more about Interstitial Lung Disease drug opportunities in our comprehensive ILD pipeline report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Interstitial Lung Disease Companies and Competitive Landscape

There are 120+ key companies, including Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, Bristol-Myers Squibb, PureTech Health, Novartis, and others, developing therapies for Interstitial Lung Disease, with candidates spanning multiple stages from discovery through Phase III.

DelveInsight's Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Disease products have been categorized under various Molecule types such as:

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Interstitial Lung Disease treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Interstitial Lung Disease Pipeline Report

• Coverage: Global
• Interstitial Lung Disease Companies: Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, Bristol-Myers Squibb, PureTech Health, Novartis, and others.
• Interstitial Lung Disease Therapies: BMS-986278, efzofitimod, nerandomilast, rentosertib, and other pipeline candidates.
• Interstitial Lung Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Interstitial Lung Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.